The serum levels of soluble HLA class I antigens (sHLA-A, -B, -C and sHLA-G) were determined in 40 HCV genotype 1-infected patients before (T0), after 3, 6, and 12 months (T3, T6, and T12) of pegylated-IFN-α plus ribavirin therapy and 6 months (T18) after the end of treatment. Twenty patients were sustained virological responders (SVR), and 20 were non-responders (NR). sHLA-A, -B, -C levels at T0 were significantly higher in both SVR (mean 10.48 μg/ml) and NR (mean 11.87 μg/ml) patients as compared to healthy controls (mean 0.34 μg/ml, p <0.0001) and HIV-infected subjects (mean 1.22 μg/ml, p <0.0001). sHLA-G levels at T0 were significantly higher in SVR (mean 24.78 ng/ml) and NR (mean 24.93 ng/ml) patients as compared to healthy controls (mean 10.34 ng/ml, p = 0.015 and p = 0.014, respectively) but were lower as compared to HIV-infected subjects (mean 48.00 ng/ml, p <0.0001). The levels of sHLA-A, -B, -C and sHLA-G significantly decreased in SVR from T0 to T18 (mean 1.64 and 1.43 ng/ml, respectively, p <0.0001) and correlated with HCV-RNA, AST, ALT, γGT, and ALP levels. The determination of soluble HLA class I levels could be proposed as a surrogate marker to discriminate SVR and NR HCV-infected patients during PEG-IFN-α plus ribavirin therapy.
- Soluble HLA
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)